Clinical

  1. Clinical

Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer

Basel, 04 July 2024 – Roche announced today that the phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial (first-line) treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, did not meet its primary endpoints of progression-free survival (PFS) […]
Written by
  1. Clinical

First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus

GAITHERSBURG, Md., July 02, 2024. artesian Therapeutics, Inc. (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that the first patient has been dosed in its Phase 2 open-label clinical trial evaluating Descartes-08 in patients with systematic lupus erythematosus (SLE). Descartes-08, Cartesian’s lead mRNA cell therapy candidate and a […]
Written by
  1. Clinical

Sirnaomics Announces Completion of STP707 Phase I Clinical Study with Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer Patients

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 28, 2024 Sirnaomics Ltd. (the “Company”, together with its subsidiaries, the “Group” or “Sirnaomics”; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced that the Group has completed STP707 Phase I clinical study with strong safety profile and […]
Written by
  1. Clinical

New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl

LUND, Sweden, June 25, 2024. Camurus today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase 3 study1 comparing weekly and monthly subcutaneous (SC) buprenorphine injections (Buvidal/Brixadi) to daily sublingual buprenorphine/naloxone (SL-BPN/NX). The data presented suggests the effectiveness in individuals with opioid dependence who use […]
Written by
  1. Clinical

First Patient Dosed in the MAD Part 2 Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

CAMBRIDGE, Mass., June 26, 2024. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced dosing of the first patient in the multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) […]
Written by
  1. Clinical

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

OSAKA, Japan and CAMBRIDGE, Massachusetts, June 22, 2024 – Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterized by the accelerated destruction of […]
Written by
  1. Clinical

Common Cholesterol-Lowering Drug Found to Slow Vision Loss in Diabetes Patients

ORLANDO, Fla., June 21, 2024. Today, findings from the Lowering Events in Non-proliferative retinopathy in Scotland (LENS) Trial revealed that fenofibrate, a medication used for many years to reduce blood fat levels, significantly reduces the progression of diabetic retinopathy, a diabetes-related eye disease. Delivered by Oxford Population Health, this is the first large-scale trial specifically […]
Written by
  1. Clinical

Clover Announces Positive Preliminary Phase Ⅰ Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults

SHANGHAI, June 18, 2024. Clover Biopharmaceuticals, Ltd. (Clover), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced positive preliminary immunogenicity and safety data in the older adult & elderly cohort from its Phase Ⅰ trial evaluating SCB-1019 – the company’s bivalent […]
Written by
  1. Clinical

Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

CRANBURY, N.J., June 12, 2024. Palatin Technologies, Inc., a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the initiation of a Phase 2 clinical study of bremelanotide for the treatment of obesity. The clinical study will evaluate the safety and efficacy of bremelanotide, a […]
Written by
  1. Clinical

Alzheimer’s drug discovery foundation’s statement on FDA advisory committee’s endorsement of donanemab

NEW YORK, June 10, 2024. Today, the FDA Peripheral and Central Nervous System Drugs Advisory Committee unanimously voted that donanemab shows clinical benefit for the treatment of early Alzheimer’s disease. If approved, donanemab would become the second disease-modifying drug for Alzheimer’s to receive full approval, expanding the arsenal of available drugs needed to treat Alzheimer’s […]
Written by

Good Reads

A proteome-wide yeast degron collection for the dynamic study of protein function

Genome-wide collections of yeast strains, known as libraries, revolutionized the way systematic studies are carried out. Specifically, libraries that involve a cellular perturbation, such as the deletion collection, have facilitated key biological discoveries. However, short-term rewiring and long-term accumulation of suppressor mutations often obscure the functional consequences of such perturbations. We present the AID library […]
Written by

Columbia Climate School Hosts Ninth Annual Sustainability Careers Reception – State of the Planet

Practitioners who attended the 2024 Sustainability Careers Reception. (*See below for names and affiliations) Last month, the Columbia Climate School hosted its ninth annual Sustainability Careers Reception at the Columbia Club in Midtown Manhattan. Thirty-three sustainability professionals and 88 Columbia students from varying backgrounds and degree pursuits gathered to discuss the ever-pressing challenges and real-world […]
Written by

Worlwide

A proteome-wide yeast degron collection for the dynamic study of protein function

Genome-wide collections of yeast strains, known as libraries, revolutionized the way systematic studies are carried out. Specifically, libraries that involve a cellular perturbation, such as the deletion collection, have facilitated key biological discoveries. However, short-term rewiring and long-term accumulation of suppressor mutations often obscure the functional consequences of such perturbations. We present the AID library […]
Written by

Columbia Climate School Hosts Ninth Annual Sustainability Careers Reception – State of the Planet

Practitioners who attended the 2024 Sustainability Careers Reception. (*See below for names and affiliations) Last month, the Columbia Climate School hosted its ninth annual Sustainability Careers Reception at the Columbia Club in Midtown Manhattan. Thirty-three sustainability professionals and 88 Columbia students from varying backgrounds and degree pursuits gathered to discuss the ever-pressing challenges and real-world […]
Written by
Scientists uncover new way viruses fight back against bacteria

Conserving high-elevation grasslands in Peru is key to protect Andean bears

Andean bears carefully select the best foraging locations and plants to maximize nutrition and avoid livestock, according to a study publishing December 18, 2024, in the open-access journal PLOS ONE by Nicholas Pilfold at the San Diego Zoo Wildlife Alliance in California, U.S., and colleagues. Andean bears, also known as ‘spectacled bears’ because of the […]
Written by

Trending

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.